Coronavirus membrane fusion mechanism offers a potential target for antiviral development

Tiffany Tang, Miya Bidon, Javier A Jaimes, Gary R Whittaker, Susan Daniel, Tiffany Tang, Miya Bidon, Javier A Jaimes, Gary R Whittaker, Susan Daniel

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has focused attention on the need to develop effective therapies against the causative agent, SARS-CoV-2, and also against other pathogenic coronaviruses (CoV) that have emerged in the past or might appear in future. Researchers are therefore focusing on steps in the CoV replication cycle that may be vulnerable to inhibition by broad-spectrum or specific antiviral agents. The conserved nature of the fusion domain and mechanism across the CoV family make it a valuable target to elucidate and develop pan-CoV therapeutics. In this article, we review the role of the CoV spike protein in mediating fusion of the viral and host cell membranes, summarizing the results of research on SARS-CoV, MERS-CoV, and recent peer-reviewed studies of SARS-CoV-2, and suggest that the fusion mechanism be investigated as a potential antiviral target. We also provide a supplemental file containing background information on the biology, epidemiology, and clinical features of all human-infecting coronaviruses, along with a phylogenetic tree of these coronaviruses.

Keywords: COVID-19; Fusion peptide; Middle east respiratory syndrome; SARS-CoV-2; Severe acute respiratory syndrome; Spike protein.

Copyright © 2020 Elsevier B.V. All rights reserved.

Figures

Fig. 1
Fig. 1
Coronavirus spike (S) protein. A. Cartoon figure of the CoV particle (top) and complete CoV viral genome (bottom). CoVs have a lipid envelope with three structural transmembrane proteins: spike (S), membrane (M), and envelope (E). The virus interior contains the viral genome encapsulated by the nucleocapsid (N) protein. The CoV single stranded genome encodes for 16 non-structural proteins, including the papain-like protease (PLpro), 3C-like protease (3CLpro), RNA-dependent RNA polymerase (RdRp), helicase (Hel), and exonuclease (ExoN). The subgenomic RNAs encode four structural proteins: spike (S; dark pink), envelope (E; dark blue), membrane (M; purple), and nucleocapsid (N; magenta) and a number of accessory proteins (Chan et al., 2020; de Wit et al., 2016). B. Cartoon figure of the CoV S protein trimer. C. The CoV S gene denoting the functional components of the protein. The CoV S protein is composed of the two subunits: S1 and S2, encompassing the major functional components: SP (signal peptide, pink); NTD (N-terminal domain; green), CTD (C-terminal domain; light blue), FP (fusion peptide; red), HR1 (heptad repeat 1; purple), HR2 (heptad repeat 2; orange), TM (transmembrane; yellow), and CP (cytoplasmic; dark blue). The S protein has two cleavage sites denoted with dark purple (S1/S2) and pink (S2’) arrows. D. Sequence alignment of S1/S2 cleavage site (dark purple arrow) and S2’ cleavage site (pink) between MERS-CoV, SARS-CoV, and SARS-CoV-2. E. Within the genome, the fusion peptide is highlighted, denoting the sequences from MERS-CoV FP and SARS-CoV FP. Red denotes the conserved residues between MERS-CoV, SARS-CoV, and SARS-CoV-2 FP sequences; blue denotes the SARS-CoV and SARS-CoV-2 FP conserved residues; green denotes the SARS-CoV and MERS-CoV FP conserved residues; purple denotes the MERS-CoV and SARS-CoV-2 conserved residues. The fusion peptide sequence of SARS-CoV-2 was determined by performing a pairwise alignment with MUSCLE through Geneious (version 2020.0.5). Amino acid sequence of the spike proteins was obtained from NCBI Genbank based on the following: SARS-CoV-2 (MN908947.3), MERS-CoV (AFS88936.1), SARS-CoV (AAP13441.1).
Fig. 2
Fig. 2
MERS-CoV (A), SARS-CoV (B), and SARS-CoV-2 (C) protein models. Models were built to show the predicted structure of the S1/S2, the S2′ cleavage site and the FP, which are not solved in cryo-EM structures. Trimers and monomers were modeled using SARS-CoV (PDB# 5X58) and MERS-CoV (PDB# 6Q05) structures using the methodology described in (Jaimes et al., 2020b). Color scheme is as described for Fig. 1.
Fig. 3
Fig. 3
Model of coronavirus dual entry pathway. This model depicts the two methods of viral entry: early pathway and late pathway. As the virus binds to its receptor (1), it can achieve entry via two routes: plasma membrane or endosome. For SARS-CoV: The presence of exogeneous and membrane bound proteases, such as trypsin and TMPRSS2, triggers the early fusion pathway (2a). Otherwise, it will be endocytosed (2b, 3). For MERS-CoV: If furin cleaved the S protein at S1/S2 during biosynthesis, exogeneous and membrane bound proteases, such as trypsin and TMPRSS2, will trigger early entry (2a). Otherwise, it will be cleaved at the S1/S2 site (2b) causing the virus to be endocytosed (3). For both: Within the endosome, the low pH activates cathepsin L (4), cleaving S2′ site, triggering the fusion pathway and releasing the CoV genome. Upon viral entry, copies of the genome are made in the cytoplasm (5), where components of the spike protein are synthesized in the rough endoplasmic reticulum (ER) (6). The structural proteins are assembled in the ER-Golgi intermediate compartment (ERGIC), where the spike protein can be pre-cleaved by furin, depending on cell type (7), followed by release of the virus from the cell (8, 9). For SARS-CoV-2: Studies currently show that SARS-CoV-2 can utilize membrane bound TMPRSS2 or endosomal cathepsin L for entry and that the S protein is processed during biosynthesis. Other factors that can influence the viral entry pathway are calcium and cholesterol (not shown).
Fig. 4
Fig. 4
Coronavirus viral fusion pathway model based on class I fusion protein understanding. The captions above the figure describe the state of the fusion protein, the captions below describe the state of the membranes. The S protein starts in the pre-fusion native state (1) and undergoes priming of the S1 subunit by relevant proteases to achieve the pre-fusion metastable state (2). Subsequent triggering by relevant proteases will enable the FP to insert in the host membrane and allow the S protein to form the pre-hairpin intermediate (3). The pre-hairpin begins to fold back on itself due to HR1 and HR2 interactions forming the pre-bundle (4), bundle (5), and eventual post-fusion stable (6) states. During the S protein foldback, the two membranes will approach each other until the outer leaflets merge (hemifusion) and eventually the inner leaflets merge (pore formation). Adapted from (White and Whittaker, 2016).
Fig. 5
Fig. 5
Model of major antiviral inhibitor pathway. This model depicts the inhibitory mechanism of a major CoV inhibitory peptide: HR2 peptide. Exogeneous HR2 peptides present during the CoV membrane fusion can competitively bind with CoV HR1. This prevents CoV HR2 from locking with HR1 and arrests the membrane fusion reaction, subsequently preventing pore formation.

References

    1. Alsaadi E.A.J., Neuman B.W., Jones I.M. A fusion peptide in the spike protein of MERS coronavirus. Viruses. 2019;11:825. doi: 10.3390/v11090825.
    1. Andersen K.G., Rambaut A., Lipkin W.I., Holmes E.C., Garry R.F. The proximal origin of SARS-CoV-2. Nat. Med. 2020;89:44–48. doi: 10.1038/s41591-020-0820-9.
    1. Barlan A., Zhao J., Sarkar M.K., Li K., McCray P.B., Perlman S., Gallagher T. Receptor variation and susceptibility to Middle East respiratory syndrome coronavirus infection. J. Virol. 2014;88:4953–4961. doi: 10.1128/JVI.00161-14.
    1. Belouzard S., Chu V.C., Whittaker G.R. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proc. Natl. Acad. Sci. Unit. States Am. 2009;106:5871–5876. doi: 10.1073/PNAS.0809524106.
    1. Belouzard S., Madu I., Whittaker G.R. Elastase-mediated activation of the severe acute respiratory syndrome coronavirus spike protein at discrete sites within the S2 domain * □ S downloaded from. J. Biol. Chem. 2010;285:22758–22763. doi: 10.1074/jbc.M110.103275.
    1. Belouzard S., Millet J.K., Licitra B.N., Whittaker G.R., Belouzard S., Millet J.K., Licitra B.N., Whittaker G.R. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses. 2012;4:1011–1033. doi: 10.3390/v4061011.
    1. Bertram S., Glowacka I., Blazejewska P., Soilleux E., Allen P., Danisch S., Steffen I., Choi S.-Y., Park Y., Schneider H., Schughart K., Pöhlmann S. TMPRSS2 and TMPRSS4 facilitate trypsin-independent spread of influenza virus in caco-2 cells. J. Virol. 2010;84:10016–10025. doi: 10.1128/JVI.00239-10.
    1. Bertram S., Glowacka I., Müller M.A., Lavender H., Gnirss K., Nehlmeier I., Niemeyer D., He Y., Simmons G., Drosten C., Soilleux E.J., Jahn O., Steffen I., Pöhlmann S. Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J. Virol. 2011;85:13363–13372. doi: 10.1128/JVI.05300-11.
    1. Biniossek M.L., Nägler D.K., Becker-Pauly C., Schilling O. Proteomic identification of protease cleavage sites characterizes prime and non-prime specificity of cysteine cathepsins B, L, and S. J. Proteome Res. 2011;10:5363–5373. doi: 10.1021/pr200621z.
    1. Bosch B.J., Bartelink W., Rottier P.J.M. Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide. J. Virol. 2008;82:8887–8890. doi: 10.1128/jvi.00415-08.
    1. Bosch J., Martina B.E.E., Van Der Zee R., Lepault J., Haijema B.J., Versluis C., Heck A.J.R., De Groot R., Osterhaus A.D.M.E., Rottier P.J.M. 2004. Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection Inhibition Using Spike Protein Heptad Repeat-Derived Peptides, PNAS.
    1. Bosch J., Van Der Zee R., De Haan C.A.M., Rottier P.J.M. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex downloaded from. J. Virol. 2003;77:8801–8811. doi: 10.1128/JVI.77.16.8801-8811.2003.
    1. Böttcher E., Matrosovich T., Beyerle M., Klenk H.-D., Garten W., Matrosovich M. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J. Virol. 2006;80:9896–9898. doi: 10.1128/JVI.01118-06.
    1. Carr C.M., Kim P.S. A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell. 1993;73:823–832. doi: 10.1016/0092-8674(93)90260-W.
    1. Chaipan C., Kobasa D., Bertram S., Glowacka I., Steffen I., Tsegaye T.S., Takeda M., Bugge T.H., Kim S., Park Y., Marzi A., Pöhlmann S. Proteolytic activation of the 1918 influenza virus hemagglutinin. J. Virol. 2009;83:3200–3211. doi: 10.1128/JVI.02205-08.
    1. Chambers P., Pringle C.R., Easton A.J. Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J. Gen. Virol. 1990;71:3075–3080. doi: 10.1099/0022-1317-71-12-3075.
    1. Chan J.F.W., Kok K.H., Zhu Z., Chu H., To K.K.W., Yuan S., Yuen K.Y. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microb. Infect. 2020;9:221–236. doi: 10.1080/22221751.2020.1719902.
    1. Channappanavar R., Lu L., Xia S., Du L., Meyerholz D.K., Perlman S., Jiang S. Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection. J. Infect. Dis. 2015;212:1894–1903. doi: 10.1093/infdis/jiv325.
    1. Chernomordik L.V., Kozlov M.M. Protein-lipid interplay in fusion and fission of biological membranes. Annu. Rev. Biochem. 2003;72:175–207. doi: 10.1146/annurev.biochem.72.121801.161504.
    1. Chernomordik L.V., Kozlov M.M. Mechanics of membrane fusion. Nat. Struct. Mol. Biol. 2008;15:675–683. doi: 10.1038/nsmb.1455.
    1. Choi S.Y., Bertram S., Glowacka I., Park Y.W., Pöhlmann S. Type II transmembrane serine proteases in cancer and viral infections. Trends Mol. Med. 2009;15:303–312. doi: 10.1016/j.molmed.2009.05.003.
    1. Cohen F.S., Melikyan G.B. The energetics of membrane fusion from binding, through hemifusion, pore formation, and pore enlargement. J. Membr. Biol. 2004;199:1–14. doi: 10.1007/s00232-004-0669-8.
    1. Coleman C.M., Sisk J.M., Mingo R.M., Nelson E.A., White J.M., Frieman M.B. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J. Virol. 2016;90:8924–8933. doi: 10.1128/jvi.01429-16.
    1. Coutard B., Valle C., de Lamballerie X., Canard B., Seidah N.G., Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antivir. Res. 2020;176:104742. doi: 10.1016/j.antiviral.2020.104742.
    1. Das D.K., Bulow U., Diehl W.E., Durham N.D., Senjobe F., Chandran K., Luban J., Munro J.B. Conformational changes in the Ebola virus membrane fusion machine induced by pH, Ca2+, and receptor binding. PLoS Biol. 2020;18 doi: 10.1371/journal.pbio.3000626.
    1. de Haan C.A.M., Rottier P.J.M. Advances in Virus Research. 2005. Molecular interactions in the assembly of coronaviruses; pp. 165–230.
    1. de Wit E., van Doremalen N., Falzarano D., Munster V.J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 2016;14:523–534. doi: 10.1038/nrmicro.2016.81.
    1. Donaldson S.H., Hirsh A., Li D.C., Holloway G., Chao J., Boucher R.C., Gabriel S.E. Regulation of the epithelial sodium channel by serine proteases in human airways. J. Biol. Chem. 2002;277:8338–8345. doi: 10.1074/jbc.M105044200.
    1. Du L., He Y., Zhou Y., Liu S., Zheng B.-J., Jiang S. The spike protein of SARS-CoV — a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 2009;7:226–236. doi: 10.1038/nrmicro2090.
    1. Du L., Yang Y., Zhou Y., Lu L., Li F., Jiang S. MERS-CoV spike protein: a key target for antivirals. Expert Opin. Ther. Targets. 2017;21:131–143. doi: 10.1080/14728222.2017.1271415.
    1. Dubé M., Etienne L., Fels M., Kielian M. Calcium-dependent rubella virus fusion occurs in early endosomes. J. Virol. 2016;90:6303–6313. doi: 10.1128/jvi.00634-16.
    1. Dubé M., Rey F.A., Kielian M. Rubella virus: first calcium-requiring viral fusion protein. PLoS Pathog. 2014;10 doi: 10.1371/journal.ppat.1004530.
    1. Dyall J., Coleman C.M., Hart B.J., Venkataraman T., Holbrook M.R., Kindrachuk J., Johnson R.F., Olinger G.G., Jahrling P.B., Laidlaw M., Johansen L.M., Lear-Rooney C.M., Glass P.J., Hensley L.E., Frieman M.B. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob. Agents Chemother. 2014;58:4885–4893. doi: 10.1128/AAC.03036-14.
    1. Epand R.M. Fusion peptides and the mechanism of viral fusion. Biochim. Biophys. Acta Biomembr. 2003;1614:116–121. doi: 10.1016/S0005-2736(03)00169-X.
    1. Fehr A.R., Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses Methods Protoc. 2015;1282:1–23. doi: 10.1007/978-1-4939-2438-7_1.
    1. Frank A.O., Vangamudi B., Feldkamp M.D., Souza-Fagundes E.M., Luzwick J.W., Cortez D., Olejniczak E.T., Waterson A.G., Rossanese O.W., Chazin W.J., Fesik S.W. Discovery of a potent stapled helix peptide that binds to the 70N domain of replication protein A. J. Med. Chem. 2014;57:2455–2461. doi: 10.1021/jm401730y.
    1. Gao J., Lu G., Qi J., Li Y., Wu Y., Deng Y., Geng H., Li H., Wang Q., Xiao H., Tan W., Yan J., Gao G.F. Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J. Virol. 2013;87:13134–13140. doi: 10.1128/jvi.02433-13.
    1. Ge M., Freed J.H. Fusion peptide from influenza hemagglutinin increases membrane surface order: an electron-spin resonance study. Biophys. J. 2009;96:4925–4934. doi: 10.1016/j.bpj.2009.04.015.
    1. Ge X.-Y., Li J.-L., Yang X.-L., Chmura A.A., Zhu G., Epstein J.H., Mazet J.K., Hu B., Zhang W., Peng C., Zhang Y.-J., Luo C.-M., Tan B., Wang N., Zhu Y., Crameri G., Zhang S.-Y., Wang L.-F., Daszak P., Shi Z.-L. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503:535–538. doi: 10.1038/nature12711.
    1. Gierer S., Bertram S., Kaup F., Wrensch F., Heurich A., Kramer-Kuhl A., Welsch K., Winkler M., Meyer B., Drosten C., Dittmer U., von Hahn T., Simmons G., Hofmann H., Pohlmann S. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can Be activated by TMPRSS2, and is targeted by neutralizing antibodies. J. Virol. 2013;87:5502–5511. doi: 10.1128/jvi.00128-13.
    1. Glende J., Schwegmann-Wessels C., Al-Falah M., Pfefferle S., Qu X., Deng H., Drosten C., Naim H.Y., Herrler G. Importance of cholesterol-rich membrane microdomains in the interaction of the S protein of SARS-coronavirus with the cellular receptor angiotensin-converting enzyme 2. Virology. 2008;381:215–221. doi: 10.1016/J.VIROL.2008.08.026.
    1. Glowacka I., Bertram S., Müller M.A., Allen P., Soilleux E., Pfefferle S., Steffen I., Tsegaye T.S., He Y., Gnirss K., Niemeyer D., Schneider H., Drosten C., Pöhlmann S. Evidence that TMPRSS2 activates the severe acute respiratory syndrome coronavirus spike protein for membrane fusion and reduces viral control by the humoral immune response. J. Virol. 2011;85:4122–4134. doi: 10.1128/JVI.02232-10.
    1. Graham R.L., Donaldson E.F., Baric R.S. A decade after SARS: strategies for controlling emerging coronaviruses. Nat. Publ. Gr. 2013;11 doi: 10.1038/nrmicro3143.
    1. Gui M., Song W., Zhou H., Xu J., Chen S., Xiang Y., Wang X. Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. Cell Res. 2017;27:119–129. doi: 10.1038/cr.2016.152.
    1. Guillén J., Kinnunen P.K.J., Villalaín J. Membrane insertion of the three main membranotropic sequences from SARS-CoV S2 glycoprotein. Biochim. Biophys. Acta Biomembr. 2008;1778:2765–2774. doi: 10.1016/J.BBAMEM.2008.07.021.
    1. Guillén J., Pérez-Berná A.J., Moreno M.R., Villalaín J. A second SARS-CoV S2 glycoprotein internal membrane-active peptide. Biophysical characterization and membrane interaction. Biochemistry. 2008;47:8214–8224. doi: 10.1021/bi800814q.
    1. Guillén J., Pérez-Berná A.J., Moreno M.R., Villalaín J. Identification of the membrane-active regions of the severe acute respiratory syndrome coronavirus spike membrane glycoprotein using a 16/18-mer peptide scan: implications for the viral fusion mechanism. J. Virol. 2005;79:1743–1752. doi: 10.1128/JVI.79.3.1743-1752.2005.
    1. Hammache D., Yahi N., Maresca M., Rard G.É., Roni P., Fantini J. Human erythrocyte glycosphingolipids as alternative cofactors for human immunodeficiency virus type 1 (HIV-1) entry: evidence for CD4-induced interactions between HIV-1 gp120 and reconstituted membrane microdomains of glycosphingolipids (Gb3 and GM3) J. Virol. 1999;73(6):5244–5248.
    1. Hamming I., Timens W., Bulthuis M.L.C., Lely A.T., Navis G.J., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J. Pathol. 2004;203:631–637. doi: 10.1002/path.1570.
    1. Harrison S.C. Viral membrane fusion. Virology. 2015;479–480:498–507. doi: 10.1016/J.VIROL.2015.03.043.
    1. Harrison S.C. Viral membrane fusion. Nat. Struct. Mol. Biol. 2008;15:690–698. doi: 10.1038/nsmb.1456.
    1. Heald-Sargent T., Gallagher T. Ready, set, fuse! The coronavirus spike protein and acquisition of fusion competence. Viruses. 2012;4:557–580. doi: 10.3390/v4040557.
    1. Hoffmann M., Kleine-Weber H., Schroeder S., Mü M.A., Drosten C., Pö S., Krü N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.-H., Nitsche A., Pö Hlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor article SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:1–10. doi: 10.1016/j.cell.2020.02.052.
    1. Hojo K., Hossain M.A., Tailhades J., Shabanpoor F., Wong L.L.L., Ong-Pålsson E.E.K., Kastman H.E., Ma S., Gundlach A.L., Rosengren K.J., Wade J.D., Bathgate R.A.D. Development of a single-chain peptide agonist of the relaxin-3 receptor using hydrocarbon stapling. J. Med. Chem. 2016;59:7445–7456. doi: 10.1021/acs.jmedchem.6b00265.
    1. Huang I.C., Bosch B.J., Li F., Li W., Kyoung H.L., Ghiran S., Vasilieva N., Dermody T.S., Harrison S.C., Dormitzer P.R., Farzan M., Rottier P.J.M., Choe H. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. J. Biol. Chem. 2006;281:3198–3203. doi: 10.1074/jbc.M508381200.
    1. Huang X., Li M., Xu Y., Zhang J., Meng X., An X., Sun L., Guo L., Shan X., Ge J., Chen J., Luo Y., Wu H., Zhang Y., Jiang Q., Ning X. Novel gold nanorod-based HR1 peptide inhibitor for Middle East respiratory syndrome coronavirus. ACS Appl. Mater. Interfaces. 2019;11 doi: 10.1021/acsami.9b04240. 19799–19807.
    1. Inoue Y., Tanaka N., Tanaka Y., Inoue S., Morita K., Zhuang M., Hattori T., Sugamura K. Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. J. Virol. 2007;81:8722–8729. doi: 10.1128/JVI.00253-07.
    1. Ishii T., Ohnuma K., Murakami A., Takasawa N., Kobayashi S., Dang N.H., Schlossman S.F., Morimoto C. 2001. CD26-mediated Signaling for T Cell Activation Occurs in Lipid Rafts through its Association with CD45RO.
    1. Iwata-Yoshikawa N., Okamura T., Shimizu Y., Hasegawa H., Takeda M., Nagata N. TMPRSS2 contributes to virus spread and immunopathology in the airways of murine models after coronavirus infection. J. Virol. JVI.01815-18. 2019;93:1815–1833. doi: 10.1128/JVI.01815-18.
    1. Jaimes J.A., Andre N.M., Chappie J.S., Millet J.K., Whittaker G.R. J. Molec. Biol.; 2020. Phylogenetic analysis and structural modeling of SARS-CoV-2 spike protein reveals an evolutionary distinct and proteolytically-sensitive activation loop. In press.
    1. Jaimes J.A., Millet J.K., Stout A.E., André N.M., Whittaker G.R. A tale of two viruses: the distinct spike glycoproteins of feline coronaviruses. Viruses. 2020;12:83. doi: 10.3390/v12010083.
    1. Jiang S., Lin K., Strick N., Neurath A.R. HIV-1 inhibition by a peptide [3] Nature. 1993;365:113. doi: 10.1038/365113a0.
    1. Jiang S., Xia S., Yu F., Lu L., Jiang Shibo, Tao X., Garron T., Du L., Lu Lu, Tseng C.-T.K. 2015. Intranasally Administered Peptidic Viral Fusion Inhibitor Protected hDPP4 Transgenic Mice from MERS-CoV Infection.
    1. Kam Y.-W., Okumura Y., Kido H., Ng L.F.P., Bruzzone R., Altmeyer R. Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro. 2009.
    1. Kawase M., Shirato K., van der Hoek L., Taguchi F., Matsuyama S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coronavirus entry. J. Virol. 2012;86:6537–6545. doi: 10.1128/jvi.00094-12.
    1. Kleine-Weber H., Elzayat M.T., Hoffmann M., Pöhlmann S. Functional analysis of potential cleavage sites in the MERS-coronavirus spike protein. Sci. Rep. 2018;8 doi: 10.1038/s41598-018-34859-w.
    1. Lai A.L., Millet J.K., Daniel S., Freed J.H., Whittaker G.R. The SARS-CoV fusion peptide forms an extended bipartite fusion platform that perturbs membrane order in a calcium-dependent manner. J. Mol. Biol. 2017;429:3875–3892. doi: 10.1016/j.jmb.2017.10.017.
    1. Lentz B.R., Malinin V., Haque M.E., Evans K. Protein machines and lipid assemblies: current views of cell membrane fusion. Curr. Opin. Struct. Biol. 2000;10:607–615.
    1. Levental I., Lingwood D., Grzybek M., Coskun Ü., Simons K. Palmitoylation regulates raft affinity for the majority of integral raft proteins. Proc. Natl. Acad. Sci. U.S.A. 2010;107:22050–22054. doi: 10.1073/pnas.1016184107.
    1. Li F. 2015. Receptor Recognition Mechanisms of Coronaviruses: a Decade of Structural Studies.
    1. Li F., Li W., Farzan M., Harrison S.C. Structural biology: structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science (80- 2005;309:1864–1868. doi: 10.1126/science.1116480.
    1. Li G.M., Li Y.G., Yamate M., Li S.M., Ikuta K. Lipid rafts play an important role in the early stage of severe acute respiratory syndrome-coronavirus life cycle. Microb. Infect. 2007;9:96–102. doi: 10.1016/j.micinf.2006.10.015.
    1. Li W., Hulswit R.J.G., Widjaja I., Raj V.S., McBride R., Peng W., Widagdo W., Tortorici M.A., Van Dieren B., Lang Y., Van Lent J.W.M., Paulson J.C., De Haan C.A.M., De Groot R.J., Van Kuppeveld F.J.M., Haagmans B.L., Bosch B.J. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 2017;114:E8508–E8517. doi: 10.1073/pnas.1712592114.
    1. Li W., Moore M.J., Vasilieva N., Sui J., Wong S.K., Berne M.A., Somasundaran M., Sullivan J.L., Luzuriaga K., Greenough T.C., Choe H., Farzan M. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi: 10.1038/nature02145.
    1. Liao Z., Cimakasky L.M., Hampton R., Nguyen D.H., Hildreth J.E.K. Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. AIDS Res. Hum. Retrovir. 2001;17:1009–1019. doi: 10.1089/088922201300343690.
    1. Liu S., Xiao G., Chen Y., He Y., Niu J., Escalante C.R., Xiong H., Farmar J., Debnath A.K., Tien P., Jiang S. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet. 2004;363:938–947. doi: 10.1016/S0140-6736(04)15788-7.
    1. Lu L., Liu Q., Zhu Y., Chan K.-H., Qin L., Li Y., Wang Q., Fuk-Woo Chan J., Du L., Yu F., Ma C., Ye S., Yuen K.-Y., Zhang R., Jiang S. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun. 2014;5 doi: 10.1038/ncomms4067.
    1. Lu M., Blacklow S.C., Kim P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat. Struct. Mol. Biol. 1995;2:1075–1082. doi: 10.1038/nsb1295-1075.
    1. Lu Y., Liu D.X., Tam J.P. Lipid rafts are involved in SARS-CoV entry into Vero E6 cells. Biochem. Biophys. Res. Commun. 2008;369:344–349. doi: 10.1016/J.BBRC.2008.02.023.
    1. Madu I.G., Belouzard S., Whittaker G.R. SARS-coronavirus spike S2 domain flanked by cysteine residues C822 and C833 is important for activation of membrane fusion. Virology. 2009;393:265–271. doi: 10.1016/j.virol.2009.07.038.
    1. Madu I.G., Roth S.L., Belouzard S., Whittaker G.R. Characterization of a highly conserved domain within the severe acute respiratory syndrome coronavirus spike protein S2 domain with characteristics of a viral fusion peptide. J. Virol. 2009;83:7411–7421. doi: 10.1128/jvi.00079-09.
    1. Marqusee S., Baldwin R.L. Helix stabilization by Glu-...Lys+ salt bridges in short peptides of de novo design. Proc. Natl. Acad. Sci. U.S.A. 1987;84:8898–8902. doi: 10.1073/pnas.84.24.8898.
    1. Martens S., McMahon H.T. Mechanisms of membrane fusion: disparate players and common principles. Nat. Rev. Mol. Cell Biol. 2008;9:543–556. doi: 10.1038/nrm2417.
    1. Masters P.S., Perlman S. Coronaviridae. Fields Virology. 2013:825–858.
    1. Matsuyama S., Nagata N., Shirato K., Kawase M., Takeda M., Taguchi F. Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2. J. Virol. 2010;84:12658–12664. doi: 10.1128/JVI.01542-10.
    1. Matsuyama S., Nao N., Shirato K., Kawase M., Saito S., Takayama I., Nagata N., Sekizuka T., Katoh H., Kato F., Sakata M., Tahara M., Kutsuna S., Ohmagari N., Kuroda M., Suzuki T., Kageyama T., Takeda M. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. Unit. States Am. 2020;202002589 doi: 10.1073/pnas.2002589117.
    1. Matsuyama S., Shirato K., Kawase M., Terada Y., Kawachi K., Fukushi S., Kamitani W. Middle East respiratory syndrome coronavirus spike protein is not activated directly by cellular furin during viral entry into target cells. J. Virol. 2018;92 doi: 10.1128/jvi.00683-18.
    1. Matsuyama S., Ujike M., Morikawa S., Tashiro M., Taguchi F. Proceedings of the National Academy of Sciences of the United States of America. 2005. Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection.
    1. Matthews T., Salgo M., Greenberg M., Chung J., DeMasi R., Bolognesi D. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 2004;3(3):215–225. doi: 10.1038/nrd1331.
    1. Menachery V.D., Yount B.L., Sims A.C., Debbink K., Agnihothram S.S., Gralinski L.E., Graham R.L., Scobey T., Plante J.A., Royal S.R., Swanstrom J., Sheahan T.P., Pickles R.J., Corti D., Randell S.H., Lanzavecchia A., Marasco W.A., Baric R.S. SARS-like WIV1-CoV poised for human emergence. Proc. Natl. Acad. Sci. U.S.A. 2016;113:3048–3053. doi: 10.1073/pnas.1517719113.
    1. Millet J.K., Whittaker G.R. Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells. Virology. 2018;517:3–8. doi: 10.1016/J.VIROL.2017.12.015.
    1. Millet J.K., Whittaker G.R. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res. 2015;202:120–134. doi: 10.1016/j.virusres.2014.11.021.
    1. Millet J.K., Whittaker G.R. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc. Natl. Acad. Sci. U.S.A. 2014;111:15214–15219. doi: 10.1073/pnas.1407087111.
    1. Mingo R.M., Simmons J.A., Shoemaker C.J., Nelson E.A., Schornberg K.L., D’souza R.S., Casanova J.E., White J.M. 2015. Ebola Virus and Severe Acute Respiratory Syndrome Coronavirus Display Late Cell Entry Kinetics: Evidence that Transport to NPC1+ Endolysosomes Is a Rate-Defining Step.
    1. Mossel E.C., Huang C., Narayanan K., Makino S., Tesh R.B., Peters C.J. Exogenous ACE2 expression allows refractory cell lines to support severe acute respiratory syndrome coronavirus replication. J. Virol. 2005;79:3846–3850. doi: 10.1128/jvi.79.6.3846-3850.2005.
    1. Munro, S. Lipid rafts: elusive or illusive? 2003 Nov 14;115(4):377-88.
    1. Nathan L., Lai A.L., Millet J.K., Straus M.R., Freed J.H., Whittaker G.R., Daniel S. Calcium ions directly interact with the Ebola virus fusion peptide to promote structure–function changes that enhance infection. ACS Infect. Dis. acsinfecdis.9b00296. 2019;6(2):250–260. doi: 10.1021/acsinfecdis.9b00296.
    1. Ochiai H., Sakai S., Hirabayashi T., Shimizu Y., Terasawa K. Inhibitory effect of bafilomycin A1, a specific inhibitor of vacuolar-type proton pump, on the growth of influenza A and B viruses in MDCK cells. Antivir. Res. 1995;27:425–430. doi: 10.1016/0166-3542(95)00040-S.
    1. Otaka A., Nakamura M., Nameki D., Kodama E., Uchiyama S., Nakamura S., Nakano H., Tamamura H., Kobayashi Y., Matsuoka M., Fujii N. Remodeling of gp41-C34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells we thank dr. Terrence R. Burke, jr., NCI, NIH, frederick, MD 21702-1201, for proofreading the manuscript and providing useful comments. This research was supported in part by a grant-in-aid for scientific research from the ministry of education, culture, sports, science and technology, Japan, the Japan society for the promotion of science, and the Japan Health science foundation. Angew. Chem. Int. Ed. 2002;41:2937. doi: 10.1002/1521-3773(20020816)41:16<2937::AID-ANIE2937>;2-J.
    1. Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T., Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun. 2020;11:1620. doi: 10.1038/s41467-020-15562-9.
    1. Park J.E., Gallagher T. Lipidation increases antiviral activities of coronavirus fusion-inhibiting peptides. Virology. 2017;511:9–18. doi: 10.1016/j.virol.2017.07.033.
    1. Park J.E., Li K., Barlan A., Fehr A.R., Perlman S., McCray P.B., Gallagher T. Proteolytic processing of middle east respiratory syndrome coronavirus spikes expands virus tropism. Proc. Natl. Acad. Sci. U.S.A. 2016;113:12262–12267. doi: 10.1073/pnas.1608147113.
    1. Peisajovich S.G., Shai Y. Viral fusion proteins: multiple regions contribute to membrane fusion. Biochim. Biophys. Acta Biomembr. 2003;1614:122–129. doi: 10.1016/S0005-2736(03)00170-6.
    1. Peng G., Sun D., Rajashankar K.R., Qian Z., Holmes K.V., Li F. Crystal structure of mouse coronavirus receptor-binding domain complexed with its murine receptor. Proc. Natl. Acad. Sci. U.S.A. 2011;108:10696–10701. doi: 10.1073/pnas.1104306108.
    1. Qian Z., Dominguez S.R., Holmes K.V. Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation. PloS One. 2013;8 doi: 10.1371/journal.pone.0076469.
    1. Qiu Z., Hingley S.T., Simmons G., Yu § Christopher, Das Sarma J., Bates † Paul, Weiss S.R. Endosomal proteolysis by cathepsins is necessary for murine coronavirus mouse hepatitis virus type 2 spike-mediated entry. J. Virol. 2006;80:5768–5776. doi: 10.1128/JVI.00442-06.
    1. Raj V.S., Mou H., Smits S.L., Dekkers D.H.W., Müller M.A., Dijkman R., Muth D., Demmers J.A.A., Zaki A., Fouchier R.A.M., Thiel V., Drosten C., Rottier P.J.M., Osterhaus A.D.M.E., Bosch B.J., Haagmans B.L. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495:251–254. doi: 10.1038/nature12005.
    1. Regan A.D., Shraybman R., Cohen R.D., Whittaker G.R. Differential role for low pH and cathepsin-mediated cleavage of the viral spike protein during entry of serotype II feline coronaviruses. Vet. Microbiol. 2008;132:235–248. doi: 10.1016/j.vetmic.2008.05.019.
    1. Reinke L.M., Spiegel M., Plegge T., Hartleib A., Nehlmeier I., Gierer S., Hoffmann M., Hofmann-Winkler H., Winkler M., Pöhlmann S. Different residues in the SARS-CoV spike protein determine cleavage and activation by the host cell protease TMPRSS2. PloS One. 2017;12 doi: 10.1371/journal.pone.0179177.
    1. Sainz B., Rausch J.M., Gallaher W.R., Garry R.F., Wimley W.C. Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein downloaded from. J. Virol. 2005;79:7195–7206. doi: 10.1128/JVI.79.11.7195-7206.2005.
    1. Shirato K., Kawase M., Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J. Virol. 2013;87:12552–12561. doi: 10.1128/jvi.01890-13.
    1. Shulla A., Heald-Sargent T., Subramanya G., Zhao J., Perlman S., Gallagher T. A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry downloaded from. J. Virol. 2011;85:873–882. doi: 10.1128/JVI.02062-10.
    1. Simmons G., Gosalia D.N., Rennekamp A.J., Reeves J.D., Diamond S.L., Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. U.S.A. 2005 doi: 10.1073/pnas.0505577102.
    1. Simmons G., Reeves J.D., Rennekamp A.J., Amberg S.M., Piefer A.J., Bates P. Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc. Natl. Acad. Sci. U.S.A. 2004;101:4240–4245. doi: 10.1073/pnas.0306446101.
    1. Simons K., Ikonen E. Functional rafts in cell membranes. Nature. 1997;387:569–572. doi: 10.1038/42408.
    1. Sisk J.M., Frieman M.B., Machamer C.E. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors. J. Gen. Virol. 2018;99:619–630. doi: 10.1099/jgv.0.001047.
    1. Song W., Gui M., Wang X., Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog. 2018;14 doi: 10.1371/journal.ppat.1007236.
    1. Straus M.R., Tang T., Lai A.L., Flegel A., Bidon M., Freed J.H., Daniel S., Whittaker G.R. Ca2+ ions promote fusion of Middle East Respiratory Syndrome coronavirus with host cells and increase infectivity. Journal of Virology. 2019;2019 doi: 10.1101/2019.12.18.881391. 12.18.881391.
    1. Sun X., Tse L.V., Ferguson A.D., Whittaker G.R. Modifications to the hemagglutinin cleavage site control the virulence of a neurotropic H1N1 influenza virus. J. Virol. 2010;84:8683–8690. doi: 10.1128/jvi.00797-10.
    1. Tripet B., Howard M.W., Jobling M., Holmes R.K., Holmes K.V., Hodges R.S. Structural characterization of the SARS-coronavirus spike S fusion protein core. J. Biol. Chem. 2004;279:20836–20849. doi: 10.1074/JBC.M400759200.
    1. Ujike M., Nishikawa † Hiroki, Otaka A., Yamamoto Naoki, Yamamoto Norio, Matsuoka M., Kodama E., Fujii N., Taguchi F. Heptad repeat-derived peptides block protease-mediated direct entry from the cell surface of severe acute respiratory syndrome coronavirus but not entry via the endosomal pathway. J. Virol. 2008;82:588–592. doi: 10.1128/JVI.01697-07.
    1. van Doremalen N., Miazgowicz K.L., Milne-Price S., Bushmaker T., Robertson S., Scott D., Kinne J., McLellan J.S., Zhu J., Munster V.J. Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. J. Virol. 2014;88:9220–9232. doi: 10.1128/jvi.00676-14.
    1. Walls A.C., Park Y.-J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. 2020. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell.
    1. Walls A.C., Tortorici M.A., Bosch B.-J., Frenz B., Rottier P.J.M., Dimaio F., Rey F.A., Veesler D. 2016. Cryo-electron Microscopy Structure of a Coronavirus Spike Glycoprotein Trimer.
    1. Wang C., Hua C., Xia S., Li W., Lu L., Jiang S. Combining a fusion inhibitory peptide targeting the MERS-CoV S2 protein HR1 domain and a neutralizing antibody specific for the S1 protein receptor-binding domain (RBD) showed potent synergism against pseudotyped MERS-CoV with or without mutations in RBD. 2019. Viruses 11.
    1. Wang C., Xia S., Zhang P., Zhang T., Wang W., Tian Y., Meng G., Jiang S., Liu K. Discovery of hydrocarbon-stapled short α-helical peptides as promising Middle East respiratory syndrome coronavirus (MERS-CoV) fusion inhibitors. J. Med. Chem. 2018;61 doi: 10.1021/acs.jmedchem.7b01732. 2018–2026.
    1. Wang H., Yang P., Liu K., Guo F., Zhang Y., Zhang G., Jiang C. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res. 2008;18:290–301. doi: 10.1038/cr.2008.15.
    1. Wang N., Shi X., Jiang L., Zhang S., Wang D., Tong P., Guo D., Fu L., Cui Y., Liu X., Arledge K.C., Chen Y.-H., Zhang L., Wang X. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 2013;23:986–993. doi: 10.1038/cr.2013.92.
    1. Warner F.J., Lew R.A., Smith A.I., Lambert D.W., Hooper N.M., Turner A.J. Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J. Biol. Chem. 2005;280:39353–39362. doi: 10.1074/jbc.M508914200.
    1. White J.M., Delos S.E., Brecher M., Schornberg K. Structures and mechanisms of viral membrane fusion proteins: multiple variations on a common theme. Crit. Rev. Biochem. Mol. Biol. 2008;43:189–219. doi: 10.1080/10409230802058320.
    1. White J.M., Whittaker G.R. Fusion of enveloped viruses in endosomes. Traffic. 2016;17:593–614. doi: 10.1111/tra.12389.
    1. Widagdo W., Okba N.M.A., Li W., de Jong A., de Swart R.L., Begeman L., van den Brand J.M.A., Bosch B.-J., Haagmans B.L. Species-specific colocalization of Middle East respiratory syndrome coronavirus attachment and entry receptors. J. Virol. 2019;93 doi: 10.1128/jvi.00107-19.
    1. Wild C.T., Shugars D.C., Greenwell T.K., McDanal C.B., Matthews T.J. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U.S.A. 1994;91:9770–9774. doi: 10.1073/pnas.91.21.9770.
    1. Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.-L., Abiona O., Graham B.S., McLellan J.S. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367:1260–1263. doi: 10.1126/science.abb2507.
    1. Xia S., Liu Q., Wang Q., Sun Z., Su S., Du L., Ying T., Lu L., Jiang S. Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res. 2014;194:200–210. doi: 10.1016/j.virusres.2014.10.007.
    1. Xia S., Yan L., Xu W., Agrawal A.S., Algaissi A., Tseng C.-T.K., Wang Q., Du L., Tan W., Wilson I.A., Jiang S., Yang B., Lu L. A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci. Adv. 2019;5:eaav4580. doi: 10.1126/sciadv.aav4580.
    1. Xia S., Zhu Y., Liu M., Lan Q., Xu W., Wu Y., Ying T., Liu S., Shi Z., Jiang S., Lu L. Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell. Mol. Immunol. 2020 doi: 10.1038/s41423-020-0374-2.
    1. Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science. 2020;80– doi: 10.1126/science.abb2762.
    1. Yang S.-T., Kreutzberger A.J.B., Lee J., Kiessling V., Tamm L.K. The role of cholesterol in membrane fusion. Chem. Phys. Lipids. 2016;199:136–143. doi: 10.1016/j.chemphyslip.2016.05.003.
    1. Yang Y., Du L., Liu C., Wang L., Ma C., Tang J., Baric R.S., Jiang S., Li F. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc. Natl. Acad. Sci. U.S.A. 2014;111:12516–12521. doi: 10.1073/pnas.1405889111.
    1. Ying T., Li H., Lu L., Dimitrov D.S., Jiang S. Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. Microb. Infect. 2015;17:142–148. doi: 10.1016/j.micinf.2014.11.008.
    1. Yuan K., Yi L., Chen J., Qu X., Qing T., Rao X., Jiang P., Hu J., Xiong Z., Nie Y., Shi X., Wang W., Ling C., Yin X., Fan K., Lai L., Ding M., Deng H. Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein. Biochem. Biophys. Res. Commun. 2004;319:746–752. doi: 10.1016/J.BBRC.2004.05.046.
    1. Yuan Y., Cao D., Zhang Y., Ma J., Qi J., Wang Q., Lu G., Wu Y., Yan J., Shi Y., Zhang X., Gao G.F. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat. Commun. 2017;8:15092. doi: 10.1038/ncomms15092.
    1. Zhang H., Wang G., Li J., Nie Y., Shi X., Lian G., Wang W., Yin X., Zhao Y., Qu X., Ding M., Deng H. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. J. Virol. 2004;78:6938–6945. doi: 10.1128/JVI.78.13.6938-6945.2004.
    1. Zheng B.J., Guan Y., He M.L., Sun H., Du L., Zheng Y., Wong K.L., Chen H., Chen Y., Lu L., Tanner J.A., Watt R.M., Niccolai N., Bernini A., Spiga O., Woo P.C.Y., Kung H.F., Yuen K.Y., Huang J.D. Synthetic peptides outside the spike protein heptad repeat regions as potent inhibitors of SARS-associated coronavirus. Antivir. Ther. 2005;10:393–403.
    1. Zhou P., Yang X.-L., Wang X.-G., Hu B., Zhang L., Zhang W., Si H.-R., Zhu Y., Li B., Huang C.-L., Chen H.-D., Chen J., Luo Y., Guo H., Jiang R.-D., Liu M.-Q., Chen Y., Shen X.-R., Wang X., Zheng X.-S., Zhao K., Chen Q.-J., Deng F., Liu L.-L., Yan B., Zhan F.-X., Wang Y.-Y., Xiao G.-F., Shi Z.-L. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: 10.1038/s41586-020-2012-7.
    1. Zhou Y., Vedantham P., Lu K., Agudelo J., Carrion R., Nunneley J.W., Barnard D., Pöhlmann S., McKerrow J.H., Renslo A.R., Simmons G. Protease inhibitors targeting coronavirus and filovirus entry. Antivir. Res. 2015;116:76–84. doi: 10.1016/J.ANTIVIRAL.2015.01.011.
    1. Zmora P., Hoffmann M., Kollmus H., Moldenhauer A.S., Danov O., Braun A., Winkler M., Schughart K., Stefan Pöhlmann X. TMPRSS11A activates the influenza A virus hemagglutinin and the MERS coronavirus spike protein and is insensitive against blockade by HAI-1. J. Biol. Chem. 2018;293:13863–13873. doi: 10.1074/jbc.RA118.001273.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa